Kanpi Duo (Indapamide, Candesartan Cilexetil)

Candesartan blocks the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone‑driven fluid retention. Indapamide acts as a thiazide‑like diuretic, inhibiting sodium and chloride reabsorption in the distal tubule, which promotes water loss and reduces extracellular fluid volume. Together they lower vascular resistance and blood volume, producing an additive antihypertensive effect.

The specific dose of Kanpi Duo is determined by the prescribing clinician based on the patient’s blood‑pressure profile, renal function, and other individual factors. Healthcare professionals adjust the regimen to achieve target blood‑pressure goals while minimizing adverse effects.

Safety of Kanpi Duo in pregnancy or while breastfeeding has not been established. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kanpi Duo combines an angiotensin‑II receptor blocker with a thiazide‑like diuretic, offering a dual mechanism that can be more effective than monotherapy for many patients. Compared with single‑agent ARBs or diuretics, the combination may achieve better blood‑pressure control with a single pill, potentially improving adherence.

Kanpi Duo tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Kanpi Duo is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious risks include severe hypotension, hyperkalemia, acute renal impairment, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience symptoms like fainting, rapid heartbeat, swelling of the face or throat, or a sudden decrease in urine output.

Kanpi Duo is contraindicated in patients with known hypersensitivity to indapamide, candesartan, or any component of the formulation. It should also be avoided in individuals with severe renal impairment, hyperkalemia, or those taking medicines that could cause dangerous potassium accumulation without close medical supervision.